Gastric cancer is a significant health concern worldwide, with high incidence rates in many European countries. The serum pepsinogen test is a non-invasive method for early detection of gastric cancer that has shown promise in several studies. The test measures the levels of two proteins, pepsinogen I and pepsinogen II, in the blood, which can indicate the presence of gastric mucosal atrophy, a precursor to gastric cancer. Studies have found that the serum pepsinogen test has high sensitivity and specificity for detecting gastric cancer in European populations, making it a promising tool for early detection and screening. Implementing this test as part of routine healthcare screenings in Europe could help detect gastric cancer at an early stage, improving patient outcomes and reducing mortality rates.